Ascendiant Capital Initiates Cytori Therapeutics With Buy

Ascendiant Capital initiated coverage on

with a Buy rating. The target price for Cytori Therapeutics is set to $1.25. Cytori Therapeutics shares have dropped 69.00 percent over the past 52 weeks, while the S&P 500 index has surged 10.96 percent in the same period. Cytori Therapeutics' shares climbed 2.69 percent to $0.730 in after-hours trading.